- Home
- ITIC vs ITOS Comparison
ITIC vs ITOS Comparison
Compare ITIC & ITOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ITIC
- ITOS
- Stock Information
- Founded
- ITIC 1972
- ITOS 2011
- Country
- ITIC United States
- ITOS United States
- Employees
- ITIC N/A
- ITOS N/A
- Industry
- ITIC Specialty Insurers
- ITOS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ITIC Finance
- ITOS Health Care
- Exchange
- ITIC Nasdaq
- ITOS Nasdaq
- Market Cap
- ITIC 440.1M
- ITOS 381.2M
- IPO Year
- ITIC N/A
- ITOS 2020
- Fundamental
- Price
- ITIC $204.13
- ITOS $10.26
- Analyst Decision
- ITIC
- ITOS Hold
- Analyst Count
- ITIC 0
- ITOS 6
- Target Price
- ITIC N/A
- ITOS $10.60
- AVG Volume (30 Days)
- ITIC 70.8K
- ITOS 764.9K
- Earning Date
- ITIC 08-05-2025
- ITOS 08-07-2025
- Dividend Yield
- ITIC 7.82%
- ITOS N/A
- EPS Growth
- ITIC 18.56
- ITOS N/A
- EPS
- ITIC 15.69
- ITOS N/A
- Revenue
- ITIC $261,197,999.00
- ITOS $35,000,000.00
- Revenue This Year
- ITIC N/A
- ITOS N/A
- Revenue Next Year
- ITIC N/A
- ITOS N/A
- P/E Ratio
- ITIC $12.82
- ITOS N/A
- Revenue Growth
- ITIC 15.27
- ITOS 177.89
- 52 Week Low
- ITIC $179.25
- ITOS $4.80
- 52 Week High
- ITIC $290.40
- ITOS $18.13
- Technical
- Relative Strength Index (RSI)
- ITIC 42.64
- ITOS 66.97
- Support Level
- ITIC $210.27
- ITOS $10.05
- Resistance Level
- ITIC $215.27
- ITOS $10.21
- Average True Range (ATR)
- ITIC 6.25
- ITOS 0.13
- MACD
- ITIC 0.06
- ITOS -0.06
- Stochastic Oscillator
- ITIC 16.25
- ITOS 81.48
About ITIC Investors Title Company
Investors Title Co operates in the title insurance and exchange services sectors. The title insurance segment, conducted through ITIC and NITIC, offers title insurance policies for residential, commercial, and industrial properties in around 22 states and the District of Columbia, with a focus on the eastern United States. The title insurance segment issues title insurance policies through approved attorneys from underwriting offices and through independent issuing agents. Title insurance policies insure titles to real estate.n The Title Insurance segment contributes the majority of the company's revenue.
About ITOS iTeos Therapeutics Inc.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.